Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in Waldenström Macroglobulinemia
NCT02180724Phase 2Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Sep 2014
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of acalabrutinib tablet (Variant 1) in Waldenström macroglobulinemia (WM) (2 arms), sponsored by Acerta Pharma. Primary endpoints: Overall Response Rate Assessed by Investigator Per IWWM 6th Criteria and Overall Response Rate Assessed by Investigator Per IWWM 3rd Criteria. Started Sep 2014; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02180724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02180724.